NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT04008797 2026-03-24
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT04203641 2025-05-06
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
Helix BioPharma Corporation
Phase 1/2 Terminated
NCT05824975 2024-11-25
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT03145558 2024-11-22
TATE
Teclison Ltd.
Phase 2 Terminated
NCT01464593 2022-10-13
ABLATE
Imunon
Phase 2 Terminated
NCT01387932 2021-11-30
HiQuality
Merit Medical Systems, Inc.
Phase 3 Terminated
NCT01655693 2021-06-02
ReLive
Valerio Therapeutics
Phase 3 Completed
NCT00108953 2014-10-31
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Phase 2 Completed
NCT00988195 2012-03-14
Study of Pegylated Human Recombinant Arginase for Liver Cancer
Bio-Cancer Treatment International Limited
Phase 1 Completed
NCT00471965 2010-09-20
EACH
Sanofi
Phase 3 Completed